Pharmaceutical Executive-03-01-2013

What can happen when reps focus on the physician-patient conversation? Al Topin reports.

S

Companies that adopt this new methodology will have a longstanding competitive advantage over those companies conducting business as usual.

Ken Getz of the Tufts University Center for the Study of Drug Development (CSDD) explains how building a stakeholder outreach agenda around the community pharmacist can lead to a better outcome in managing the complex ins and outs of a trial protocol.

Innovation in hub program design for patient scrip data and clinical support services can lead to increased market share in the hotly contested specialty medicine space.

Chinese policies are to pose new opportunities and challenges for Big Pharma companies active in the country.

A proactive approach to talent and organization planning is the hidden trump card in prevailing with payers.

Pressure for action on key enforcement and regulatory issues may prompt congressional action this year.

European Commision blocks the authorization of a life-saving liver drug outside of France.

In 2012, Merck's diabetes franchise became the highest-selling product family in its 122-year history.

Timely engagement is the key to expanding the use of companion diagnostics.

Big Pharma takes a fresh licking in our latest audit of US press coverage of business and policy issues.

As small biotech firms test the water in partnerships with Big Pharma, the best calling card is a well-framed strategy on intellectual property.

China's pharmaceutical industry is making record gains. Four years ago, China was the world's fifth largest market. Now, it has bypassed France and Germany to become the third largest. By 2015, China will pass Japan to rival only the United States for number one.